Literature DB >> 12068288

HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.

Christian Grimm1, Andreas Wenzel, Matthias Groszer, Helmut Mayser, Mathias Seeliger, Marijana Samardzija, Christian Bauer, Max Gassmann, Charlotte E Remé.   

Abstract

Erythropoietin (Epo) is upregulated by hypoxia and provides protection against apoptosis of erythroid progenitors in bone marrow and brain neurons. Here we show in the adult mouse retina that acute hypoxia dose-dependently stimulates expression of Epo, fibroblast growth factor 2 and vascular endothelial growth factor via hypoxia-inducible factor-1alpha (HIF-1alpha) stabilization. Hypoxic preconditioning protects retinal morphology and function against light-induced apoptosis by interfering with caspase-1 activation, a downstream event in the intracellular death cascade. In contrast, induction of activator protein-1, an early event in the light-stressed retina, is not affected by hypoxia. The Epo receptor required for Epo signaling localizes to photoreceptor cells. The protective effect of hypoxic preconditioning is mimicked by systemically applied Epo that crosses the blood retina barrier and prevents apoptosis even when given therapeutically after light insult. Application of Epo may, through the inhibition of apoptosis, be beneficial for the treatment of different forms of retinal disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12068288     DOI: 10.1038/nm723

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  142 in total

Review 1.  Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2011-12-14       Impact factor: 3.633

2.  Dose-dependent treatment of optic nerve crush by exogenous systemic mutant erythropoietin.

Authors:  Timothy A Sullivan; Eldon E Geisert; Justin P Templeton; Tonia S Rex
Journal:  Exp Eye Res       Date:  2012-01-27       Impact factor: 3.467

3.  Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.

Authors:  Claudia Bartels; Kira Späte; Henning Krampe; Hannelore Ehrenreich
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 4.  An overview of drug development with special emphasis on the role of visual electrophysiological testing.

Authors:  Mitchell Brigell; Cun-Jian Dong; Serge Rosolen; Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

Review 5.  Winding through the WNT pathway during cellular development and demise.

Authors:  F Li; Z Z Chong; K Maiese
Journal:  Histol Histopathol       Date:  2006-01       Impact factor: 2.303

6.  Low-oxygen culture conditions extend the multipotent properties of human retinal progenitor cells.

Authors:  Petr Y Baranov; Budd A Tucker; Michael J Young
Journal:  Tissue Eng Part A       Date:  2014-01-24       Impact factor: 3.845

7.  Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Authors:  Jörn Karhausen; Glenn T Furuta; John E Tomaszewski; Randall S Johnson; Sean P Colgan; Volker H Haase
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Circulating levels of erythropoietin and its relation to arterial stiffness in patients with hypertension.

Authors:  Omer Gedikli; Abdulkadir Kiris; Caner Karahan
Journal:  Int J Clin Exp Med       Date:  2013-09-01

9.  Acute inactivation of the VHL gene contributes to protective effects of ischemic preconditioning in the mouse kidney.

Authors:  Mitsuko Iguchi; Yoshihiko Kakinuma; Atsushi Kurabayashi; Takayuki Sato; Taro Shuin; Seung-Beom Hong; Laura S Schmidt; Mutsuo Furihata
Journal:  Nephron Exp Nephrol       Date:  2008-10-27

10.  Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation.

Authors:  Daqing Ma; Ta Lim; Jing Xu; Haidy Tang; Yanjie Wan; Hailin Zhao; Mahmuda Hossain; Patrick H Maxwell; Mervyn Maze
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.